Renalytix AI Reports Fiscal Year Financials
Company Announcements

Renalytix AI Reports Fiscal Year Financials

Renalytix AI (GB:RENX) has released an update.

Renalytix AI, an AI-enabled diagnostics firm specializing in kidney disease, reported a total revenue of $2.3 million for FY24, with losses before tax totaling $44.9 million due to significant impairment and fair value adjustments. The company’s total assets stood at $7.3 million, including $4.7 million in cash, by the end of June 2024. Investors are anticipated to see differences between US GAAP and IFRS audited results, specifically in the treatment of intangibles.

For further insights into GB:RENX stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks UK Auto-Generated NewsdeskRenalytix Sees Major Shift in Voting Rights
TipRanks UK Auto-Generated NewsdeskRenalytix PLC Sees Major Voting Rights Shift
TipRanks UK Auto-Generated NewsdeskRenalytix Adjusts Share Capital Amid Fundraising Shortfall
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App